论文部分内容阅读
目的对复方甘草酸苷联合还原型谷胱甘肽治疗酒精性肝病的疗效及安全性进行研究,证实该疗法的临床价值。方法选取本院肝病科2011年3月~2013年3月治疗的酒精性肝病患者218例为研究对象,采用随机数字表法将其分为两个研究组,每组109例。采用复方甘草酸苷联合还原型谷胱甘肽治疗的为观察组;仅采用还原型谷胱甘肽治疗的为对照组。治疗一个月后就临床疗效及不良反应进行组间比较及统计学分析。结果观察组研究对象治疗总有效率为93.6%高于对照组87.2%的总有效率,且具有显著差异性(P<0.05);观察组不良反应发生率为10.1%低于对照组,差异有统计学意义(P<0.05)。结论复方甘草酸苷联合还原型谷胱甘肽在酒精性肝病的治疗中具有疗效显著,安全性高等优势,适于临床推广使用。
Objective To study the efficacy and safety of compound glycyrrhizin combined with reduced glutathione for the treatment of alcoholic liver disease and to confirm its clinical value. Methods Two hundred and eighty-eight patients with alcoholic liver disease who were treated in our hospital from March 2011 to March 2013 were selected as study subjects, and divided into two groups (109 cases in each group) by random number table. Compound glycyrrhizin combined with reduced glutathione treatment for the observation group; only treated with reduced glutathione as a control group. One month after treatment, clinical efficacy and adverse reactions were compared between groups and statistical analysis. Results The total effective rate of the observation group was 93.6% higher than that of the control group (87.2%), with significant difference (P <0.05). The incidence of adverse reactions in the observation group was 10.1% lower than that of the control group Statistical significance (P <0.05). Conclusion Compound glycyrrhizin combined with reduced glutathione in the treatment of alcoholic liver disease has a significant effect, high safety advantages, suitable for clinical use.